Clinical trials: Ulcerative Colitis, Active
Ulcerative Colitis
A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.
The proposed study is a randomized, double-blind,placebo-controlled, multicenter phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active ulcerative colitis.
- Trial name
- NCT03675477
- Testing
- SHR0302
- Where
- 67 sites in United States, China and 3 more
- Volunteers
- 164 people
- Sponsor
- Reistone Biopharma Company Limited
Colitis, Ulcerative
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is effective in the treatment of chronic active ulcerative colitis patients not responding to available therapy.
- Trial name
- COLLECT (NCT01493960)
- Testing
- Cobitolimod
- Where
- 37 sites in Czechia, France and 5 more
- Volunteers
- 131 people
- Sponsor
- InDex Pharmaceuticals
Ulcerative Colitis
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
The primary objectives of this study are as follows: To assess the safety and tolerability of escalating single and multiple doses of GS-5745 (andecaliximab) in participants with moderate to severe ulcerative colitis (UC) as…
- Trial name
- NCT01831427
- Testing
- Andecaliximab
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 74 people
- Sponsor
- Gilead Sciences
Ulcerative Colitis
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT02895100
- Testing
- PTG-100
- Where
- 98 sites in United States, Australia and 15 more
- Volunteers
- 98 people
- Sponsor
- Protagonist Therapeutics, Inc.
Colitis, Ulcerative
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).
- Trial name
- NCT00487539
- Testing
- Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg
- Where
- 200 sites in United States, Australia and 23 more
- Volunteers
- 1,065 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis…
- Trial name
- OCTAVE (NCT01458951)
- Testing
- tofacitinib
- Where
- 182 sites in United States, Australia and 27 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Ulcerative Colitis
Oral OKT3 for the Treatment of Active Ulcerative Colitis
This study will assess the safety and efficacy of orally delivered short-term OKT3 in participants with active ulcerative colitis.
- Trial name
- NCT01287195
- Testing
- Oral OKT3, Omeprazole
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Brigham and Women's Hospital
Ulcerative Colitis
Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
The study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. Investigational product will be administered as subcutaneous injection.
- Trial name
- NCT01482884
- Testing
- tralokinumab
- Where
- 28 sites in Czechia, France and 4 more
- Volunteers
- 147 people
- Sponsor
- AstraZeneca
Ulcerative Colitis (UC)
Efficacy & Safety of TD-1473 in Ulcerative Colitis
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
- Trial name
- RHEA (NCT03758443)
- Testing
- TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 239 people
- Sponsor
- Theravance Biopharma
Ulcerative Colitis
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05785715
- Testing
- NX-13 250mg, NX-13 750mg
- Where
- 35 sites in United States, Belgium and 2 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Ulcerative Colitis
Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
The purpose of this study is to evaluate the safety and efficacy of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), compared with placebo.
- Trial name
- NCT00659802
- Testing
- HMPL-004 low dose, HMPL-004 high dose
- Volunteers
- 224 people
- Sponsor
- Hutchison Medipharma Limited
Colitis, Ulcerative
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- PURSUIT 2 (NCT03596645)
- Testing
- Golimumab, Infliximab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis, IBD
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by…
- Trial name
- Expedition (NCT03616821)
- Testing
- Brazikumab
- Where
- 125 sites in United States, Canada and 17 more
- Volunteers
- 242 people
- Sponsor
- AstraZeneca
Acute Ulcerative Colitis
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05.
- Trial name
- Precision-UC (NCT01903252)
- Testing
- TP05, Asacol 400 mg
- Where
- Switzerland
- Volunteers
- 817 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
The purpose of this study was to evaluate efficacy of cobitolimod treatment at different dose levels and frequencies compared to placebo in patients with moderate to severe left-sided ulcerative colitis.
- Trial name
- CONDUCT (NCT03178669)
- Testing
- cobitolimod
- Where
- 64 sites in Czechia, France and 8 more
- Volunteers
- 213 people
- Sponsor
- InDex Pharmaceuticals
Ulcerative Colitis
Efficacy and Safety of BBT-401-1S in Ulcerative Colitis
This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis.
- Trial name
- NCT03800420
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- Bridge Biotherapeutics, Inc.
Colitis, Ulcerative
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- VEGA (NCT03662542)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1
- Where
- 82 sites in United States, Argentina and 7 more
- Volunteers
- 214 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
- Trial name
- GLADIATOR UC (NCT04607837)
- Testing
- Etrasimod
- Where
- 288 sites in United States, Australia and 16 more
- Volunteers
- 234 people
- Sponsor
- Pfizer
Colitis, Ulcerative
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- ASTRO (NCT05528510)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 236 sites in United States, Argentina and 23 more
- Volunteers
- 418 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
This is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult participants with active moderate to severe UC.
- Trial name
- NCT01671956
- Testing
- Bertilimumab
- Where
- 6 sites in Israel
- Volunteers
- 32 people
- Sponsor
- Alexion Pharmaceuticals, Inc.